FilingReader Intelligence
Walvax RSV mRNA vaccine trial approved in China
August 3, 2025 at 08:39 AM UTC•By FilingReader AI
Walvax Biotechnology announced that China's National Medical Products Administration has accepted its respiratory syncytial virus mRNA vaccine clinical trial application, developed with Fudan University and Shanghai Bluebird Bio.
No RSV vaccines are currently approved domestically in China, while three are approved internationally including GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA. Global RSV vaccine sales reached approximately $4 billion in 2023-2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Walvax Biotechnology publishes news
Free account required • Unsubscribe anytime